Premium
The Value of the Measurement of Serum Prostate Specific Antigen in Patients with Benign Prostatic Hyperplasia and Untreated Prostate Cancer
Author(s) -
ARMITAGE T. G.,
COOPER E. H.,
NEWLING D. W. W.,
ROBINSON M. R. G.,
APPLEYARD I.
Publication year - 1988
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1988.tb04431.x
Subject(s) - medicine , hyperplasia , urology , prostate cancer , prostate specific antigen , prostate , pca3 , cancer , urinary retention , oncology
Summary— Serum prostate specific antigen (PSA) levels were measured in 139 patients with benign prostatic hyperplasia (BPH) and in 88 patients with prostate cancer who were managed by deferred treatment. Acute urinary retention and large prostate glands tended to be associated with high PSA levels, but at levels > 10 ng/ml there was a significant risk of carcinoma being found on subsequent histological examination. The risk of progression of untreated prostate cancer was associated with levels of PSA > 20 ng/ml and with a high rate of change of PSA level. The value of measuring PSA in these patients is discussed.